NASDAQ:CAPR - Capricor Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$1.39 -0.01 (-0.71 %)
(As of 06/20/2018 02:56 AM ET)
Previous Close$1.40
Today's Range$1.36 - $1.47
52-Week Range$0.63 - $4.25
Volume205,025 shs
Average Volume367,956 shs
Market Capitalization$41.63 million
P/E Ratio-3.16
Dividend YieldN/A
Beta-3.22
Capricor Therapeutics logoCapricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.

Receive CAPR News and Ratings via Email

Sign-up to receive the latest news and ratings for CAPR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CAPR
CUSIPN/A
Phone310-358-3200

Debt

Debt-to-Equity RatioN/A
Current Ratio9.94
Quick Ratio9.94

Price-To-Earnings

Trailing P/E Ratio-3.16
Forward P/E Ratio-2.90
P/E GrowthN/A

Sales & Book Value

Annual Sales$2.67 million
Price / Sales15.15
Cash FlowN/A
Price / CashN/A
Book Value$0.44 per share
Price / Book3.16

Profitability

EPS (Most Recent Fiscal Year)($0.44)
Net Income$2.43 million
Net Margins110.98%
Return on Equity-485.43%
Return on Assets-85.83%

Miscellaneous

Employees40
Outstanding Shares29,110,000

Capricor Therapeutics (NASDAQ:CAPR) Frequently Asked Questions

What is Capricor Therapeutics' stock symbol?

Capricor Therapeutics trades on the NASDAQ under the ticker symbol "CAPR."

How were Capricor Therapeutics' earnings last quarter?

Capricor Therapeutics Inc (NASDAQ:CAPR) announced its earnings results on Wednesday, March, 14th. The biotechnology company reported ($0.11) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.10) by $0.01. The biotechnology company earned $0.48 million during the quarter, compared to analyst estimates of $0.63 million. Capricor Therapeutics had a net margin of 110.98% and a negative return on equity of 485.43%. View Capricor Therapeutics' Earnings History.

When is Capricor Therapeutics' next earnings date?

Capricor Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, August, 8th 2018. View Earnings Estimates for Capricor Therapeutics.

What price target have analysts set for CAPR?

3 brokers have issued 1 year price targets for Capricor Therapeutics' stock. Their forecasts range from $2.15 to $9.00. On average, they anticipate Capricor Therapeutics' share price to reach $6.05 in the next twelve months. View Analyst Ratings for Capricor Therapeutics.

Who are some of Capricor Therapeutics' key competitors?

Who are Capricor Therapeutics' key executives?

Capricor Therapeutics' management team includes the folowing people:
  • Frank I. Litvack M.D., Independent Executive Chairman of the Board (Age 59)
  • Linda Marban Ph.D., President, Chief Executive Officer, Director (Age 51)
  • Anthony Bergmann, Chief Financial Officer, Principal Accounting Officer (Age 32)
  • Karen G. Krasney J.D., Executive Vice President, General Counsel (Age 62)
  • Thomas Lyle Copmann Ph.D., Vice President - Regulatory Affairs and Drug Development (Age 61)
  • Houman Hemmati M.D., Ph.D., Vice President - Medical & Clinical Development, New Therapies
  • Luis Rodriguez-Borlado Ph.D., Vice President - Regenerative Therapies
  • Rachel Smith Ph.D., Vice President - Research & Development (Age 36)
  • Deborah Ascheim M.D., Chief Medical Officer
  • Joshua A. Kazam, Director (Age 40)

Has Capricor Therapeutics been receiving favorable news coverage?

News stories about CAPR stock have been trending somewhat positive this week, according to Accern Sentiment. The research firm identifies negative and positive news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Capricor Therapeutics earned a daily sentiment score of 0.22 on Accern's scale. They also assigned news headlines about the biotechnology company an impact score of 44.90 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

How do I buy shares of Capricor Therapeutics?

Shares of CAPR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Capricor Therapeutics' stock price today?

One share of CAPR stock can currently be purchased for approximately $1.39.

How big of a company is Capricor Therapeutics?

Capricor Therapeutics has a market capitalization of $41.63 million and generates $2.67 million in revenue each year. The biotechnology company earns $2.43 million in net income (profit) each year or ($0.44) on an earnings per share basis. Capricor Therapeutics employs 40 workers across the globe.

How can I contact Capricor Therapeutics?

Capricor Therapeutics' mailing address is 8840 WILSHIRE BLVD 2ND FLOOR, BEVERLY HILLS CA, 90211. The biotechnology company can be reached via phone at 310-358-3200 or via email at [email protected]


MarketBeat Community Rating for Capricor Therapeutics (CAPR)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  151 (Vote Outperform)
Underperform Votes:  172 (Vote Underperform)
Total Votes:  323
MarketBeat's community ratings are surveys of what our community members think about Capricor Therapeutics and other stocks. Vote "Outperform" if you believe CAPR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CAPR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.